Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome... In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease in LDL-C levels.
- Mechanism
- Curator reviewed
Muraglitazar is one of the dual peroxisome proliferator-activated receptor (PPAR) agonists. It interacts with both PPAR alpha and gamma receptors. Working through the PPAR gamma receptor, muraglitazar has very potent insulin-sensitizing effects on liver and muscle to lower the blood sugar levels. working through the PPAR alpha receptor, muraglitazar is very potent in terms of lowering the triglycerides and raising the HDL [high-density lipoprotein] cholesterol and converting small dense LDL [low-density lipoprotein] particles to larger, more buoyant particles, so it promotes a very good lipid profile from the standpoint of prevention of atherosclerosis.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
- Formula / weight
- C29H28N2O7 · 516.55 g/mol (avg)
- Code names
- BMS-298585 · BMS-298585-01 · MK-0478
Resolves to
IRLWJILLXJGJTD-UHFFFAOYSA-NSMILESCOC1=CC=C(OC(=O)N(CC(O)=O)CC2=CC=C(OCCC3=C(C)OC(=N3)C3=CC=CC=C3)C=C2)C=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Muraglitazar, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account